Anti-DLL3 antibody drug conjugates for treating cancer
Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.
1. A method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an antibody drug conjugate (ADC) comprising an anti-DLL3 antibody covalently linked through a linker to one or more pyrrolobenzodiazepines (PBDs), wherein the one or more PBDs is/are:
2. The method of claim 1 , wherein the cancer is lung cancer.
3. The method of claim 2 , wherein the cancer is small cell lung cancer.
4. The method of claim 1 , wherein the cancer comprises a neuroendocrine tumor.
5. The method of claim 4 , wherein the cancer is large cell neuroendocrine carcinoma.
6. The method of claim 1 , wherein the cancer is thyroid cancer.
7. The method of claim 1 , wherein the cancer is prostate cancer.
8. The method of claim 1 , wherein the linker comprises a cleavable linker.
9. The method of claim 1 , wherein the anti-DLL3 antibody is covalently linked to more than one PBD.
10. The method of claim 1 , wherein the ADC has a drug loading of 2.
11. The method of claim 1 , wherein the anti-DLL3 antibody is a chimeric antibody, CDR-grafted antibody, or humanized antibody.
12. The method of claim 1 , wherein the anti-DLL3 antibody comprises three CDRs of a light chain variable region set forth as SEQ ID NO: 405 and three CDRs of a heavy chain variable region set forth as SEQ ID NO: 407.
13. The method of claim 12 , wherein the anti-DLL3 antibody comprises residues 24-34 of SEQ ID NO: 405 for CDR-L1, residues 50-56 of SEQ ID NO: 405 for CDR-L2, residues 89-97 of SEQ ID NO: 405 for CDR-L3, residues 31-35 of SEQ ID NO: 407 for CDR-H1, residues 50-65 of SEQ ID NO: 407 for CDR-H2, and residues 95-102 of SEQ ID NO: 407 for CDR-H3, wherein the residues are numbered according to Kabat.
14. The method of claim 13 , wherein the anti-DLL3 antibody comprises a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 405 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 407.
15. The method of claim 1 , wherein the pharmaceutical composition comprises a DAR of 2+/−0.4.
16. The method of claim 15 , wherein the pharmaceutical composition comprises less than 30% of non-predominant ADC species.
17. A method of reducing the frequency of tumor initiating cells in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an antibody drug conjugate (ADC) comprising an anti-DLL3 antibody covalently linked through a linker to one or more pyrrolobenzodiazepines (PBDs), wherein the one or more PBDs is/are:
18. The method of claim 17 wherein the reduction in frequency is determined using
(a) flow cytometric analysis of tumor cell surface markers known to enrich for tumor initiating cells or immunohistochemical detection of tumor cell surface markers known to enrich for tumor initiating cells;
(b) in vitro or in vivo limiting dilution analysis;
(c) in vivo limiting dilution analysis comprising transplant of live human tumor cells into immunocompromised mice; or
(d) in vitro limiting dilution analysis comprising limiting dilution deposition of live human tumor cells into in vitro colony supporting conditions.
19. A method of sensitizing a tumor in a subject for treatment with an anti-cancer agent, to said subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an antibody drug conjugate (ADC) comprising an anti-DLL3 antibody covalently linked through a linker to one or more pyrrolobenzodiazepines (PBDs), wherein the one or more PBDs is/are:
20. A method of inhibiting metastasis in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an antibody drug conjugate (ADC) comprising an anti-DLL3 antibody covalently linked through a linker to one or more pyrrolobenzodiazepines (PBDs), wherein the one or more PBDs is/are:
21. The method of claim 20 wherein the subject undergoes a debulking procedure before or after the administration of the pharmaceutical composition.
22. A method of performing maintenance therapy to reduce cancer recurrence in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an antibody drug conjugate (ADC) comprising an anti-DLL3 antibody covalently linked through a linker to one or more pyrrolobenzodiazepines (PBDs), wherein the one or more PBDs is/are:
23. A method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an antibody drug conjugate (ADC) comprising:
wherein Ab comprises an anti-DLL3 antibody.
24. The method of claim 23 , wherein Ab is covalently linked to more than one PBD.
25. The method of claim 23 , wherein the ADC has a drug loading of 2.
26. The method of claim 23 , wherein the cancer is small cell lung cancer.
27. A method of treating lung cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an antibody drug conjugate (ADC) comprising an anti-DLL3 antibody covalently linked through a linker to one or more pyrrolobenzodiazepines (PBDs),
wherein the anti-DLL3 antibody comprises a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 405 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 407;
wherein the one or more PBDs is/are:
and
wherein the pharmaceutical composition comprises a DAR of 2+/−0.4.
28. The method of claim 27 , wherein the lung cancer is small cell lung cancer.
29. A method of treating lung cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an antibody drug conjugate (ADC) comprising:
wherein Ab comprises an anti-DLL3 antibody comprising a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 405 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 407; and
wherein the pharmaceutical composition comprises a DAR of 2+/−0.4.
30. The method of claim 29 , wherein the lung cancer is small cell lung cancer.